{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:14:14Z","timestamp":1794924854452,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001652","name":"Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting millions worldwide, leading to inflammation, joint damage, and reduced quality of life. Although biological disease-modifying antirheumatic drugs (bDMARDs) are effective, they are costly, and up to 40% of patients do not achieve remission within six months. Accurate prediction of treatment response is crucial for optimizing care, minimizing side effects, and enhancing cost efficiency. This study proposes a robust machine learning framework for predicting six-month remission in RA patients using baseline routine clinical data. The framework also integrates risk stratification and explainability to enhance its clinical applicability. We evaluated multiple machine learning models, AdaBoost, Random Forest, XGBoost, and Support Vector Machines, using data from Austrian RA patients. We externally validated the results on an independent dataset from the Erlangen Hospital. To improve the reliability of probability estimates for actionable risk stratification, we employed calibration techniques, including Platt scaling, Isotonic regression, Beta calibration, and Spline calibration. We generated calibration curves to assess and visualize the alignment between predicted probabilities and observed outcomes. In addition, we used SHapley Additive exPlanations (SHAP) to analyze the contributions of different patient characteristics to the prediction of RA remission. AdaBoost demonstrated stronger performance than the other models, achieving an accuracy of 85.71% and a Brier score of 0.13 with isotonic regression calibration. SHAP identified DAS28, visual analog scales (VAS), age, and swollen joint count (SJC) as important characteristics for the prediction of RA remission. We also stratified patients into low-, medium-, and high-risk categories based on model predictions to support follow-up scheduling and treatment prioritization. Our framework predicts RA remission before the initiation of bDMARD therapy. It enables personalized care, actionable risk stratification, and optimized resource allocation. Its robustness was validated on two different individual cohort datasets, which highlights its potential for integration into routine clinical workflows.<\/jats:p>","DOI":"10.1038\/s41598-025-09975-z","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:49:33Z","timestamp":1751636973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A robust machine learning approach to predicting remission and stratifying risk in rheumatoid arthritis patients treated with bDMARDs"],"prefix":"10.1038","volume":"15","author":[{"given":"Fatemeh","family":"Salehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Salin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Smarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnd","family":"Kleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Fritsch-Stork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern M.","family":"Eskofier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"9975_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","volume":"423","author":"GS Firestein","year":"2003","unstructured":"Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 423, 356\u2013361 (2003).","journal-title":"Nature"},{"key":"9975_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos, Y. & Drosos, A. A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4, 130\u2013136 (2005).","journal-title":"Autoimmun. Rev."},{"key":"9975_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205\u20132219 (2011).","journal-title":"N. Engl. J. Med."},{"key":"9975_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"9975_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth, A. et al. Failure of anti-TNF treatment in patients with rheumatoid arthritis: the pros and cons of the early use of alternative biological agents. Autoimmun. Rev. 18, 102398 (2019).","journal-title":"Autoimmun. Rev."},{"key":"9975_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.62.5.482","volume":"62","author":"D Aletaha","year":"2003","unstructured":"Aletaha, D., Kapral, T. & Smolen, J. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann. Rheum. Dis. 62, 482\u2013486 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"9975_CR7","unstructured":"Antoni, C. & Braun, J. Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol. 20, S\u2013152 (2002)."},{"key":"9975_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1586\/erp.13.24","volume":"13","author":"I De La Torre","year":"2013","unstructured":"De La Torre, I. et al. Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification. Expert Rev. Pharmacoecon. Outcomes Res. 13, 407\u2013414 (2013).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"9975_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4078\/jrd.2020.27.3.159","volume":"27","author":"Y Kim","year":"2020","unstructured":"Kim, Y. et al. The impact of the amendment of the Korean national health insurance reimbursement criteria for anti-tumor necrosis factor-\u03b1 agents on treatment pattern, clinical response and persistence in patients with rheumatoid arthritis. J. Rheum. Dis. 27, 159\u2013167 (2020).","journal-title":"J. Rheum. Dis."},{"key":"9975_CR10","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s12325-016-0372-z","volume":"33","author":"A Batticciotto","year":"2016","unstructured":"Batticciotto, A., Ravasio, R., Riva, M. & Sarzi-Puttini, P. Efficacy and treatment costs of monotherapy with bdmards in the treatment of rheumatoid arthritis in patients intolerant to or inappropriate to continue treatment with methotrexate. Adv. Ther. 33, 1360\u20131373 (2016).","journal-title":"Adv. Ther."},{"key":"9975_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/ard.2007.083675","volume":"67","author":"W Kievit","year":"2008","unstructured":"Kievit, W. et al. The effectiveness and medication costs of three anti-tumour necrosis factor \u03b1\u00a0agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann. Rheum. Dis. 67, 1229\u20131234 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"9975_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","volume":"124","author":"A van der Heide","year":"1996","unstructured":"van der Heide, A. et al. The effectiveness of early treatment with second-line antirheumatic drugs: a randomized, controlled trial. Ann. Intern. Med. 124, 699\u2013707 (1996).","journal-title":"Ann. Intern. Med."},{"key":"9975_CR13","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/jcm13133890","volume":"13","author":"F Salehi","year":"2024","unstructured":"Salehi, F. et al. Machine learning prediction of treatment response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis. J. Clin. Med. 13, 3890 (2024).","journal-title":"J. Clin. Med."},{"key":"9975_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-024-03277-x","volume":"26","author":"D Ukalovic","year":"2024","unstructured":"Ukalovic, D. et al. Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg. Arthritis Res. Ther. 26, 44 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"9975_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/acr2.11101","volume":"2","author":"JE Collins","year":"2020","unstructured":"Collins, J. E. et al. Predicting remission among patients with rheumatoid arthritis starting tocilizumab monotherapy: model derivation and remission score development. ACR Open Rheumatol. 2, 65\u201373 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"9975_CR16","doi-asserted-by":"publisher","first-page":"rkaa005","DOI":"10.1093\/rap\/rkaa005","volume":"4","author":"M H\u00fcgle","year":"2020","unstructured":"H\u00fcgle, M., Omoumi, P., van Laar, J. M., Boedecker, J. & H\u00fcgle, T. Applied machine learning and artificial intelligence in rheumatology. Rheumatol. Adv. Pract. 4, rkaa005 (2020).","journal-title":"Rheumatol. Adv. Pract."},{"key":"9975_CR17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/rheumatology\/keab521","volume":"61","author":"N Yoosuf","year":"2022","unstructured":"Yoosuf, N. et al. Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. Rheumatology 61, 1680\u20131689 (2022).","journal-title":"Rheumatology"},{"key":"9975_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010204","volume":"18","author":"B Prasad","year":"2022","unstructured":"Prasad, B. et al. Atrpred: A machine learning based tool for clinical decision making of anti-TNF treatment in rheumatoid arthritis patients. PLoS Comput. Biol. 18, e1010204 (2022).","journal-title":"PLoS Comput. Biol."},{"key":"9975_CR19","doi-asserted-by":"publisher","first-page":"20169","DOI":"10.1038\/s41598-021-99625-x","volume":"11","author":"W Kim","year":"2021","unstructured":"Kim, W. et al. Association of tlr 9 gene polymorphisms with remission in patients with rheumatoid arthritis receiving tnf-\u03b1\u00a0inhibitors and development of machine learning models. Sci. Rep. 11, 20169 (2021).","journal-title":"Sci. Rep."},{"key":"9975_CR20","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese, F. et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 r4ra randomized trial. Nat. Med. 28, 1256\u20131268 (2022).","journal-title":"Nat. Med."},{"key":"9975_CR21","first-page":"e334","volume":"28","author":"V Venerito","year":"2022","unstructured":"Venerito, V. et al. A machine learning approach for predicting sustained remission in rheumatoid arthritis patients on biologic agents. JCR: J. Clin. Rheumatol. 28, e334\u2013e339 (2022).","journal-title":"JCR: J. Clin. Rheumatol."},{"key":"9975_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631662","volume":"12","author":"M Luque-T\u00e9var","year":"2021","unstructured":"Luque-T\u00e9var, M. et al. Integrative clinical, molecular, and computational analysis identify novel biomarkers and differential profiles of anti-tnf response in rheumatoid arthritis. Front. Immunol. 12, 631662 (2021).","journal-title":"Front. Immunol."},{"key":"9975_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-015-0856-z","volume":"17","author":"B Rintelen","year":"2016","unstructured":"Rintelen, B. et al. Validity of data collected in bioreg, the Austrian register for biological treatment in rheumatology: current practice of bdmard therapy in rheumatoid arthritis in Austria. BMC Musculoskelet. Disord. 17, 1\u20138 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"9975_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells, G. et al. Validation of the 28-joint disease activity score (das28) and European league against rheumatism response criteria based on c-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the das28 based on erythrocyte sedimentation rate. Ann. Rheum. Dis. 68, 954\u2013960 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"9975_CR25","doi-asserted-by":"crossref","unstructured":"Van Buuren, S. Flexible Imputation of Missing Data (CRC Press, 2018).","DOI":"10.1201\/9780429492259"},{"key":"9975_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained equations: issues and guidance for practice. Stat. Med. 30, 377\u2013399 (2011).","journal-title":"Stat. Med."},{"key":"9975_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1146\/annurev.psych.58.110405.085530","volume":"60","author":"JW Graham","year":"2009","unstructured":"Graham, J. W. Missing data analysis: Making it work in the real world. Annu. Rev. Psychol. 60, 549\u2013576 (2009).","journal-title":"Annu. Rev. Psychol."},{"key":"9975_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur, M. J., Stuart, E. A., Frangakis, C. & Leaf, P. J. Multiple imputation by chained equations: what is it and how does it work?. Int. J. Methods Psychiatr. Res. 20, 40\u201349 (2011).","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"9975_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12963-025-00364-2","volume":"23","author":"K Junaid","year":"2025","unstructured":"Junaid, K., Kiran, T., Gupta, M., Kishore, K. & Siwatch, S. How much missing data is too much to impute for longitudinal health indicators? a preliminary guideline for the choice of the extent of missing proportion to impute with multiple imputation by chained equations. Popul. Health Metrics 23, 2 (2025).","journal-title":"Popul. Health Metrics"},{"key":"9975_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/ard-2022-223413","volume":"82","author":"P Studenic","year":"2023","unstructured":"Studenic, P. et al. American college of rheumatology\/eular remission criteria for rheumatoid arthritis: 2022 revision. Ann. Rheum. Dis. 82, 74\u201380 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"9975_CR31","doi-asserted-by":"crossref","unstructured":"Lichtenstein, S., Fischhoff, B. & Phillips, L.\u00a0D. Calibration of probabilities: The state of the art. In Decision Making and Change in Human Affairs: Proceedings of the Fifth Research Conference on Subjective Probability, Utility, and Decision Making, Darmstadt, 1\u20134 September, 1975, 275\u2013324 (Springer, 1977).","DOI":"10.1007\/978-94-010-1276-8_19"},{"key":"9975_CR32","unstructured":"Platt, J.\u00a0C. & Smola, A. Advances in large margin classifiers (1999)."},{"key":"9975_CR33","doi-asserted-by":"crossref","unstructured":"Leeuw, J.\u00a0d., Hornik, K. & Mair, P. Isotone optimization in r: pool-adjacent-violators algorithm (pava) and active set methods (2009).","DOI":"10.18637\/jss.v032.i05"},{"key":"9975_CR34","unstructured":"Kull, M., de Menezes e Silva Filho, T. & Flach, P.\u00a0A. Beta calibration: a well-founded and easily implemented improvement on logistic calibration for binary classifiers. In International Conference on Artificial Intelligence and Statistics (2017)."},{"key":"9975_CR35","unstructured":"Lucena, B. Spline-based probability calibration. arXiv preprint arXiv:1809.07751 (2018)."},{"key":"9975_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jclinepi.2009.11.009","volume":"63","author":"K Rufibach","year":"2010","unstructured":"Rufibach, K. Use of brier score to assess binary predictions. J. Clin. Epidemiol. 63, 938\u2013939 (2010).","journal-title":"J. Clin. Epidemiol."},{"key":"9975_CR37","unstructured":"Lundberg, S. A unified approach to interpreting model predictions. arXiv preprint arXiv:1705.07874 (2017)."},{"key":"9975_CR38","first-page":"4765","volume":"30","author":"M Scott","year":"2017","unstructured":"Scott, M. et al. A unified approach to interpreting model predictions. Adv. Neural. Inf. Process. Syst. 30, 4765\u20134774 (2017).","journal-title":"Adv. Neural. Inf. Process. Syst."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09975-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09975-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09975-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:49:35Z","timestamp":1751636975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09975-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9975"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09975-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5941518\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23960"}}